{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:12:49Z","timestamp":1783149169910,"version":"3.54.6"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016274"],"award-info":[{"award-number":["2016274"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116131","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:40:22Z","timestamp":1763772022000},"page":"116131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-4246","authenticated-orcid":false,"given":"Ursula M.","family":"Vogl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-6284","authenticated-orcid":false,"given":"Sara","family":"Merler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Angrisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-0350","authenticated-orcid":false,"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-6268","authenticated-orcid":false,"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6018","authenticated-orcid":false,"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4783-4788","authenticated-orcid":false,"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-6555","authenticated-orcid":false,"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116131_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. report from the 2024 advanced prostate cancer consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116131_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2021.09.036","article-title":"Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings","volume":"160","author":"Vogl","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116131_bib3","unstructured":"EAU Guidelines. Edn.presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5. \u3008https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf\u3009, accessed 10 Sept. 2025."},{"key":"10.1016\/j.ejca.2025.116131_bib4","unstructured":"NCCN Clinical Practice Guidelines in Oncology Prostate Cancer Version 2.2025 NCCNN, All rights reserved. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf, accessed 10 Sept.2025."},{"key":"10.1016\/j.ejca.2025.116131_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2020","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejca.2025.116131_bib7","series-title":"A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial)","first-page":"LBA04","author":"Spratt","year":"2025"},{"key":"10.1016\/j.ejca.2025.116131_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.10.009","article-title":"Radiotherapy plus long-term adjuvant androgen deprivation with a luteinizing hormone\u2013releasing hormone antagonist versus agonist in patients with very high-risk localized or locally advanced prostate cancer: The EORTC GUCG-1414 phase 3 randomized trial","author":"Zilli","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"_2","key":"10.1016\/j.ejca.2025.116131_bib9","first-page":"S1","article-title":"Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Nguyen","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib11","series-title":"Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)","author":"Ratnakumaran","year":"2025"},{"key":"10.1016\/j.ejca.2025.116131_bib12","series-title":"Androgen-deprivation therapy and high-dose definitive radiotherapy \u00b1 whole-pelvic RT in patients with unfavorable intermediate or favorable high-risk prostate cancer: early results of a phase III randomized controlled trial","author":"Roach","year":"2025"},{"key":"10.1016\/j.ejca.2025.116131_bib13","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib14","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2025.43.16_suppl.5000","article-title":"Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer","volume":"43","author":"DeWeese","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib15","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ijrobp.2025.06.1024","article-title":"Phase 3, randomized, placebo controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer","volume":"123","author":"Gejerman","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2025.116131_bib16","doi-asserted-by":"crossref","DOI":"10.4103\/aja.aja_96_20","article-title":"Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2021","journal-title":"Asian J Androl"},{"key":"10.1016\/j.ejca.2025.116131_bib17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116131_bib18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2025.116131_bib20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib21","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","author":"Shore","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V\u2013STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential Impact of (68)Ga-PSMA-11 PET\/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"10.1016\/j.ejca.2025.116131_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2020.08.021","article-title":"Role of 68-Ga-PSMA-PET\/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients","volume":"151","author":"Onal","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12885-022-09493-5","article-title":"Phase III randomised controlled trial on PSMA PET\/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol","volume":"22","author":"Staal","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.116131_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116131_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2019.01.045","article-title":"Androgen Deprivation Therapy and Salvage Radiotherapy: Are We Missing Something?","volume":"76","author":"Gonzalez-San Segundo","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116131_bib28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2023.41.6_suppl.303","article-title":"FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)","volume":"41","author":"Nguyen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2024.42.4_suppl.131","article-title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL)","volume":"42","author":"Posadas","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib31","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib37","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejca.2025.116131_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib39","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib40","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE 1): a multicentre, open-label, randomised, phase 3 study with a 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116131_bib41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116131_bib42","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE 1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejca.2025.116131_bib43","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejca.2025.116131_bib44","doi-asserted-by":"crossref","unstructured":"Fizazi K., Clarke N.W., De Santis M., Uemura H., Fay A.P., Karadurmus N., et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Annals of Oncology. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.004.","DOI":"10.1016\/j.annonc.2025.10.004"},{"issue":"_2","key":"10.1016\/j.ejca.2025.116131_bib45","first-page":"S1","article-title":"3-weekly docetaxel 75 mg\/m2 vs 2-weekly docetaxel 50 mg\/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial","volume":"36","author":"Grimm","year":"2025","journal-title":"Ann Oncol"},{"issue":"_2","key":"10.1016\/j.ejca.2025.116131_bib46","first-page":"S1","article-title":"Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00231-1","article-title":"Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol","author":"Gillessen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116131_bib49","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.euf.2024.06.008","article-title":"Is There a Place for De-escalating Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer?","volume":"10","author":"Turco","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ejca.2025.116131_bib50","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib51","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300171","article-title":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","volume":"3","author":"Fizazi","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2025.116131_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.116131_bib53","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2025.43.16_suppl.5017","article-title":"Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Baldini","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib54","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/ijc.33706","article-title":"Phase I clinical trial of HC-1119: A deuterated form of enzalutamide","volume":"149","author":"Li","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2025.116131_bib55","article-title":"Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study","volume":"43","author":"Schweizer","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib56","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.2025.43.5_suppl.22","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9)","volume":"43","author":"Niazi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib58","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Niazi","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib59","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116131_bib61","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116131_bib62","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34","author":"Sartor","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib63","unstructured":"Fizazi K., Chi K.N., Shore N.D., Herrmann K., de Bono J.S., Castellano D., et al. Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Annals of Oncology."},{"key":"10.1016\/j.ejca.2025.116131_bib64","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2308","article-title":"LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)","volume":"35","author":"Sartor","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib65","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116131_bib66","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib67","unstructured":"\u3008https:\/\/www.globenewswire.com\/news-release\/2024\/11\/13\/2980452\/0\/en\/Curium-Announces-ECLIPSE-Trial-Has-Met-Primary-Endpoint-Demonstrating-a-Statistically-Significant-and-Clinically-Meaningful-Benefit-for-Patients-With-PSMA-Positive-Metastatic-Castr.html\u3009, accessed 10 Sept. 2025."},{"key":"10.1016\/j.ejca.2025.116131_bib68","series-title":"177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial","author":"Kishan","year":"2025"},{"key":"10.1016\/j.ejca.2025.116131_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer","volume":"102","author":"Keating","year":"2010","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.ejca.2025.116131_bib70","doi-asserted-by":"crossref","first-page":"S1258","DOI":"10.1016\/j.annonc.2024.08.2312","article-title":"LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer","volume":"35","author":"Langley","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116131_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.2025.43.5_suppl.21","article-title":"Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer\u2014Randomised comparison from the STAMPEDE trial platform","volume":"43","author":"James","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib73","doi-asserted-by":"crossref","first-page":"12067","DOI":"10.1200\/JCO.2024.42.16_suppl.12067","article-title":"Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96\/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w)","volume":"42","author":"Moos","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2025.43.5_suppl.163","article-title":"Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96\/12)","volume":"43","author":"Templeton","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib75","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","article-title":"Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial","volume":"6","author":"Shore","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib76","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","article-title":"Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial","volume":"6","author":"Shore","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejca.2025.116131_bib77","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High-Risk Assessment: Breast O, Pancreatic, and Prostate. Version 1.2026, NCCNN, All rights reserved. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf\u3009; assessed 04.10.2025."},{"key":"10.1016\/j.ejca.2025.116131_bib78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer\u2014metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116131_bib79","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-\/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116131_bib80","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:29:03Z","timestamp":1773919743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":80,"alternative-id":["S0959804925010172"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116131","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116131"}}